CMML is clinically diverse malignant clonal hematopoietic stem cell disorder characterized by persistent peripheral monocytosis, bone marrow dysplasia and with features of both myelodysplastic and myeloproliferative neoplasms (1). Generally, long term prognosis is poor with a median overall survival of 30 months and a relatively high risk of leukemic transformation, up to 30 % (2). Hypomethylating agents belong to a class of drugs which inhibit DNA methyltransferase and consequently reduce DNA methylation. Utilization of HMA in CMML has been reported with seemingly unsatisfying results with overall response rates between 30 and 60% and median overall survival between 12 and 37 months (3,4). Previously only a few predictive factors (increased bone marrow blast count and proliferative features) were found to be associated with shorter survival (5). Surprisingly only age, but none of the other disease characteristics, was a prediction for a response(6). In this case report, we describe an effective long term use of azacitidine in a patient with CMML and tried to find factors, which may contribute to long term azacitidine efficacy.
Endometrial cancer is the sixth most common cancer in women worldwide. It is associated with aberrant actions of steroid hormones, estrogens and progesterone, but also with enhanced inflammation and reduced cellular differentiation. Here, we show data on demographic and histopathological characteristics of 51 patients with endometrial cancer, together with data on correlations between the expression of 38 genes involved in estrogen and progesterone actions, inflammation and differentiation, and demographic characteristics. We also show data on changes in gene expression of these 38 genes according to histopathological and clinical characteristics of these patients. This article includes data referenced in the manuscript entitled »STAR and AKR1B10 are down-regulated in high-grade endometrial cancer by Sinreih et al. (in press) [1].
Background: Polish Adult Leukemia group demonstrated that addition of cladribine to standard daunorubicin + cytarabine (DAC) induction chemotherapy for acute myeloid leukaemia (AML) increases remission rate and prolongs overall survival. The approach was subsequently included in NCCN guidelines. At University Medical Centre Ljubljana, Slovenia we started using DAC induction regimen in May 2014 for all patients up to 60 years of age, eligible for intensive chemotherapy. We compared the outcome of patients treated with DA3+7 (in use from January 2012 until April 2014) with the outcome of patients treated with DAC in the period from May 2014 to December 2017. Methods: We retrospectively analyzed all consecutive patients diagnosed with AML between January 2012 and December 2017, aged 60 or less, who were eligible for intensive chemotherapy according to ECOG performance status, echocardiography and spirometry results. Exclusion criteria were severe organ impairment and acute promyelocytic leukaemia. The induction regimen in the period January 2012 -April 2014 consisted of daunorubicin 60 mg/m2 on days 1,3 and 5 and continuous infusion of cytarabine 200 mg/m2 from day 1 to 7 (DA3+7) while in the period May 2014 - December 2017 cladribine 5 mg/m2 in a 3-hour infusion on days 1 through 5 was added to DA3+7. Consolidation treatment was the same for both groups and consisted of 2 or 3 courses of cytarabine. Eligible patients with unfavorable characteristics (monosomal /complex kariotype, FLT3 ITD or KMT2A rearrangements, therapy-related AML) proceeded to alogenic bone marrow transplantation (BMT). Patients who did not achieve remission after induction chemotherapy received rescue chemotherapy and also proceeded to alogenic BMT. The efficacy of induction treatment was assessed by bone marrow aspiration in the aplasia between days 7 and 10 after the last day of induction chemotherapy, and before the first consolidation therapy. Results: 50 patients with AML (27 women, 23 men) were treated with DA3+7. 58 patients (31 women, 27 men) were treated with DAC. There were no significant differences in the median age of the patients in both groups (54,4 years in the DA group vs 54,5 years in the DAC group; p=0,853). There were also no significant differences in the proportion of patients with unfavorable cytogenetics or therapy-related AML (50% in the DA group vs 51,7% in the DAC group; p= 0,858). Remission after induction chemotherapy was achieved in a significantly higher proportion of patients in the DAC group (47/58= 81,0%) compared to the DA group (30/50 =60%; p=0,016). Survival was significantly higher in the DAC group compared to the DA group (p=0,034) with a median survival of 18 months in the DA group, while in the DAC group the median survival was not reached. No diferences in toxicity between the DA and DAC regimen were observed. Conclusions: We confirmed results from other research groups by demonstrating improved remisssion induction rate and improved overall survival of AML patients aged 60 years or less treated with DAC induction compared to the standard DA3+7 induction chemotherapy. For evaluating the long-term overall survival further follow up is needed. Figure. Figure. Disclosures No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.